🇺🇸 SECNOVO NORDISK A SCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 21:11:30·⟳ 抓取 21:11:57 +27s·⚡ 决策 08-31 21:24:41 +12m44s·56.8 天前
诺和诺德披露既有股份回购计划的每周执行进展
该6-K是既有股份回购计划的定期执行公告，核心金额、期限和回购框架均已在此前公告确定；本次新增的是过去一周交易流水，缺少能改变短线预期的增量事实。
📄 原文NOVO NORDISK A S↗ 原文
----- f6k_083126.htm ----- 6-K 1 f6k_083126.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 诺和诺德（NVO.US）
不做：本次只是既有回购计划的例行周度执行公告，没有新增额度、加速回购或业绩预期差，短线无明确edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
诺和诺德披露了8月24日至28日的回购执行进展，但回购计划总额DKK 15 billion、子计划额度和执行期均为既有安排。本次没有新增资本配置决定、业绩变化、监管进展或超预期回购加速，不能形成对诺和诺德（NVO.US）或其哥本哈根B股的正期望交易。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 high ↗
关键理由
- 回购执行本身对股东回报方向偏正面，但本次只是既有计划的机械周度披露。
- 累计回购金额和库存股比例已按计划推进，没有披露超出原计划的新增额度或加速信号。
主要风险
- 若市场原本预期公司会扩大或加速回购，本公告没有提供这类增量，短线催化不足。
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；核心判断来自公告性质本身为既有计划的例行进展。
方向:例行回购进展公告通常更像资本管理披露而非新增催化；本轮信息已可直接判定缺少交易增量。
涨幅量级:没有使用先例校准幅度，因为本次不进入交易。
形态:无足够可比先例进入权衡。
原文全文
展开原文 · 4,153 字
----- f6k_083126.htm -----
6-K
1
f6k_083126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 31, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 August 2026 –
On 6 May 2026, Novo
Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 24 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
15,170,000
4,590,476,842
24 August 2026
210,000
301.87
63,393,359
25 August 2026
210,000
306.00
64,259,374
26 August 2026
210,000
308.60
64,805,405
27 August 2026
210,000
296.89
62,346,025
28 August 2026
210,000
297.11
62,392,810
Accumulated under the programme
16,220,000
4,907,673,815
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 45,019,876 B shares of DKK
0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 28 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 30,979,179
B shares at an average share price of DKK 281.08 per B share equal to a transaction value of DKK 8,707,673,805.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 53 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 31, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
6-K
1
f6k_083126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 31, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 August 2026 –
On 6 May 2026, Novo
Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 24 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
15,170,000
4,590,476,842
24 August 2026
210,000
301.87
63,393,359
25 August 2026
210,000
306.00
64,259,374
26 August 2026
210,000
308.60
64,805,405
27 August 2026
210,000
296.89
62,346,025
28 August 2026
210,000
297.11
62,392,810
Accumulated under the programme
16,220,000
4,907,673,815
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 45,019,876 B shares of DKK
0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 28 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 30,979,179
B shares at an average share price of DKK 281.08 per B share equal to a transaction value of DKK 8,707,673,805.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 53 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 31, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。